Galimedix Therapeutics Presents New Data on Patient-Tailored Microperimetry in GA Study

Galimedix Therapeutics, Inc., a Phase 2 clinical-stage biotechnology company, has presented new data from its ongoing Phase 2 eDREAM study at the 26th EURETINA Congress. The study, which is evaluating the efficacy of GAL-101 eye drops in geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), has demonstrated the robustness and potential of patient-tailored microperimetry (MP) as a functional measurement in GA studies.

The eDREAM study, officially known as NCT06659549, is a Phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. It is designed to assess the efficacy and safety of GAL-101 eye drops in patients with GA. The study is planned to enroll 110 patients across clinical sites in the United States, Europe, and Israel. Participants are randomized 1:1 to receive GAL-101 eye drops or placebo.

The data presented at EURETINA 2026 support the high repeatability of patient-tailored microperimetry for functional evaluation in GA. Microperimetry is a specialized vision test that measures sensitivity at specific retinal locations. In the eDREAM study, a patient-tailored lesion-specific grid is created based on each patient’s retinal imaging to plot test points around the atrophic area. This individualized sensitivity map can then be directly compared with imaging of the underlying retina, enabling a more precise assessment of how structural changes relate to functional vision loss.

Data from the eDREAM study are being presented in several oral presentations and posters at EURETINA. More details are available on the company’s website.

Patient-tailored MP demonstrates robustness and potential advantages over current functional measurements in GA. In eDREAM, following the first screening visit, a patient-tailored lesion-specific grid is created based on each patient’s retinal imaging to plot test points around the atrophic area. This individualized sensitivity map can then be directly compared with imaging of the underlying retina, enabling a more precise assessment of how structural changes relate to functional vision loss.

As a first step, repeatability and test-retest characteristics were analyzed via three independent tests that took place at two separate visits. Results demonstrated good short-term repeatability in this cohort, and as employed in eDREAM, this procedure was well managed by all parties. These findings support the robustness of patient-tailored MP for functional assessment in GA clinical trials.

Other functional baseline measurements assessed in the eDREAM study include best-corrected visual acuity (BCVA), low-luminance visual acuity (LLVA), and microperimetric sensitivity in five central foveal points. All three assessments showed no systematic bias in the two repeat tests. The tests were complimentary, with BCVA being the most precise but showing the least reliability. Defining baseline as the mean of two tests markedly reduced measurement error, suggesting duplicate testing should be the default design for trials using these important assessments in macular disease.

To further assess the potential of patient-tailored MP, clinicians correlated structural changes in the retina, determined by optical coherence tomography (OCT), such as layer thickness, length of area of damage, or area of atrophy, with changes in point-wise retinal function measured with MP. Readings were able to show that damaged light-sensing cells or photoreceptor disruption (PRD) occurred in the same location as damage to the supporting retinal pigment epithelium (RPE) layer underneath them. This accurate co-localization strongly predicted focal scotomas, areas of low or no vision. Other structural measures, such as outer nuclear layer, provided critical data regarding local tissue function, particularly within structurally compromised points. MP detected a high prevalence of discordant loci, points in the retina where the structural appearance and the measured visual function did not match, highlighting the complex pathophysiological heterogeneity of the peri-atrophic region.

These findings further support the value of tailored-grid methodology for functional mapping and suggest incorporating continuous OCT metrics or severity grading rather than relying on simple binary structural classification. Finally, standardized thickness units remain essential to accurately translating these anatomical coefficients into clinically meaningful functional outcomes.

The eDREAM data presented at EURETINA 2026 provide new evidence supporting patient-tailored MP as a sensitive and precise functional readout in GA and its potential role in future clinical studies.